BridgeBio Pharma, Inc. Operating Income Loss

• BridgeBio Pharma, Inc. showed an increase of +11.7% in Operating Income Loss from 2024 to 2025.
• This data is from BridgeBio Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), BridgeBio Pharma, Inc.'s Operating Income Loss has declined by 1,093.4%.
• Historical annual values: Fiscal year 2025: -$523.41 million | Fiscal year 2024: -$592.97 million | Fiscal year 2023: -$607.37 million | Fiscal year 2022: -$512.20 million | Fiscal year 2021: -$576.63 million | Fiscal year 2020: -$474.48 million | Fiscal year 2019: -$266.24 million | Fiscal year 2018: -$183.66 million | Fiscal year 2017: -$43.86 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026